Literature DB >> 26503999

Relationship Between Metabolic Reprogramming and Mitochondrial Activity in Cancer Cells. Understanding The Anticancer Effect of Metformin and Its Clinical Implications.

Massimiliano Cazzaniga1, Bernardo Bonanni2.   

Abstract

Metabolic reprogramming refers to the ability of cancer cells to alter their metabolism in order to support the increased energy request due to continuous growth, rapid proliferation, and other characteristics typical of neoplastic cells. This adaptation comprises of some important bioenergetic changes that, in contrary to conventional and outdated concepts, require an unchanged mitochondrial activity for their efficacy. This review highlights the characteristics of metabolic reprogramming, the role of mitochondrial activity in this particular setting, and the therapeutic possibility of targeting pathways of energy metabolism in cancer cells, with particular emphasis on metformin efficacy and its relationship with mitochondria metabolism. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Metabolic reprogramming; metformin; mitochondria; review

Mesh:

Substances:

Year:  2015        PMID: 26503999

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  16 in total

1.  Acute renal metabolic effect of metformin assessed with hyperpolarised MRI in rats.

Authors:  Haiyun Qi; Per M Nielsen; Marie Schroeder; Lotte B Bertelsen; Fredrik Palm; Christoffer Laustsen
Journal:  Diabetologia       Date:  2017-09-21       Impact factor: 10.122

2.  Energetic metabolic reprogramming in Jurkat DFF40-deficient cancer cells.

Authors:  Merve Kulbay; Bruno Johnson; Guillaume Ricaud; Marie-Noëlle Séguin-Grignon; Jacques Bernier
Journal:  Mol Cell Biochem       Date:  2022-04-22       Impact factor: 3.842

3.  Reversal of multidrug resistance of hepatocellular carcinoma cells by metformin through inhibiting NF-κB gene transcription.

Authors:  Wei Wu; Jun-Ling Yang; Yi-Lang Wang; Han Wang; Min Yao; Li Wang; Juan-Juan Gu; Yin Cai; Yun Shi; Deng-Fu Yao
Journal:  World J Hepatol       Date:  2016-08-18

4.  Suppression of Kaposi's Sarcoma-Associated Herpesvirus Infection and Replication by 5'-AMP-Activated Protein Kinase.

Authors:  Fan Cheng; Meilan He; Jae U Jung; Chun Lu; Shou-Jiang Gao
Journal:  J Virol       Date:  2016-06-24       Impact factor: 5.103

5.  Downregulation of Rab27A contributes to metformin-induced suppression of breast cancer stem cells.

Authors:  Feixue Feng; Jianping Zhang; Xiaoxuan Fan; Fang Yuan; Yinghao Jiang; Ruihua Lv; Yanxia Ma
Journal:  Oncol Lett       Date:  2017-07-08       Impact factor: 2.967

Review 6.  Targeting MYC Dependence by Metabolic Inhibitors in Cancer.

Authors:  Himalee S Sabnis; Ranganatha R Somasagara; Kevin D Bunting
Journal:  Genes (Basel)       Date:  2017-03-31       Impact factor: 4.096

Review 7.  Blood and Cancer: Cancer Stem Cells as Origin of Hematopoietic Cells in Solid Tumor Microenvironments.

Authors:  Ghmkin Hassan; Masaharu Seno
Journal:  Cells       Date:  2020-05-22       Impact factor: 6.600

8.  CaMeRe: A Novel Tool for Inference of Cancer Metabolic Reprogramming.

Authors:  Haoyang Li; Juexiao Zhou; Huiyan Sun; Zhaowen Qiu; Xin Gao; Ying Xu
Journal:  Front Oncol       Date:  2020-02-25       Impact factor: 6.244

9.  Different effect of testosterone and oestrogen on urinary excretion of metformin via regulating OCTs and MATEs expression in the kidney of mice.

Authors:  Rui He; Ligen Ai; Dandan Zhang; Lili Wan; Taishan Zheng; Jun Yin; Huijuan Lu; Junxi Lu; Fengdi Lu; Fang Liu; Weiping Jia
Journal:  J Cell Mol Med       Date:  2016-07-29       Impact factor: 5.310

10.  Differential responses on energy metabolic pathway reprogramming between genotoxic and non-genotoxic hepatocarcinogens in rat liver cells.

Authors:  Yuko Ito; Kota Nakajima; Yasunori Masubuchi; Satomi Kikuchi; Fumiyo Saito; Yumi Akahori; Meilan Jin; Toshinori Yoshida; Makoto Shibutani
Journal:  J Toxicol Pathol       Date:  2019-07-28       Impact factor: 1.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.